UNC.F UCB SA

Healthcare Biotechnology Frankfurt Exchange
291.70 EUR
Close of Nov 13, 2026
197.85 301.00
Market cap
EUR 55.6B
P/E
25.8x
P/B
4.84x
ROE
14.3%
Dividend yield
0.47%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is UNC.F undervalued?

Graham number
Price291.70
Graham value123.94
Premium135.4%

UNC.F trades 135.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

UCB SA fundamental analysis

No fundamental analysis for UCB SA yet.

UCB SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs …

Full company profile